Therefore, further investigation should be conducted to clarify the accuracy of a combined analysis of SAA1 expression, the amounts of tumor-infiltrating mast cells resting, and the types of mutation driven prior to SAA1 inhibitor treatment for ccRCC patients. This evidence concerns the gene SAA1 and neoplasm.